Haleon (LON:HLN) Sets New 12-Month High - Still a Buy?

Haleon plc (LON:HLN - Get Free Report)'s stock price hit a new 52-week high during mid-day trading on Saturday . The stock traded as high as GBX 402.30 ($5.15) and last traded at GBX 395.30 ($5.06), with a volume of 76461156 shares traded. The stock had previously closed at GBX 382.40 ($4.89).

Analyst Upgrades and Downgrades

Separately, Berenberg Bank raised their target price on Haleon from GBX 456 ($5.83) to GBX 457 ($5.85) and gave the company a "buy" rating in a research note on Friday, February 28th.

Haleon Stock Down 2.0 %

The company has a debt-to-equity ratio of 53.36, a quick ratio of 0.93 and a current ratio of 0.84. The stock's 50-day moving average price is GBX 381.23 and its two-hundred day moving average price is GBX 379.81. The stock has a market capitalization of £36.71 billion, a PE ratio of 34.21, a P/E/G ratio of 1.49 and a beta of 0.19.

Haleon (LON:HLN - Get Free Report) last announced its quarterly earnings data on Friday, February 28th. The company reported GBX 15.80 ($0.20) earnings per share for the quarter. Haleon had a net margin of 9.66% and a return on equity of 6.54%. As a group, analysts expect that Haleon plc will post 19.5033282 EPS for the current fiscal year.

About Haleon

Haleon LSE / NYSE: HLN is a world-leading consumer health company, with a clear purpose to deliver better everyday health with humanity. In July 2022, it listed as an independent company on the London and New York Stock Exchanges. Haleon's portfolio spans five global categories including Oral Health, Vitamins, Minerals and Supplements (VMS), Pain Relief, Respiratory Health and Digestive Health and other.